| 2024-02-20 | +72.8% | legal | SEC EDGAR | IOVA 8-K: 1.01, 8.01 (SEC Filing) |
| 2024-02-20 | +72.8% | legal | SEC EDGAR | IOVA 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-07-22 | +58.6% | legal | Seeking Alpha | Iovance climbs after FDA rejection for Replimunes skin cancer drug |
| 2022-05-26 | -57.0% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-05-08 | -44.7% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2024-08-08 | +32.6% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2026-02-23 | +32.0% | earnings | Seeking Alpha | Iovance Biotherapeutics Q4 2025 Earnings Preview |
| 2026-02-23 | +32.0% | analyst | Yahoo Finance | Iovance (IOVA) Shares New Amtagvi Data, Analysts Stay Positive - Yahoo Finance |
| 2021-05-19 | -31.3% | legal | SEC EDGAR | IOVA 8-K: 5.02 (SEC Filing) |
| 2026-02-24 | +30.9% | analyst | Seeking Alpha | Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade) |
| 2026-02-24 | +30.9% | earnings | Seeking Alpha | Iovance outlines surge toward profitability with 30% revenue growth in Q4 2025 while expanding Amtagvi adoption and pipeline |
| 2026-02-24 | +30.9% | earnings | Seeking Alpha | Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript |
| 2026-02-24 | +30.9% | earnings | Seeking Alpha | Iovance surges on Q4 results, Amtagvi data in soft tissue sarcoma |
| 2026-02-24 | +30.9% | earnings | Seeking Alpha | Iovance Biotherapeutics GAAP EPS of -$0.18 in-line, revenue of $86.71M beats by $5.7M |
| 2026-02-24 | +30.9% | legal | SEC EDGAR | IOVA 8-K: 2.02, 8.01 (SEC Filing) |
| 2026-02-24 | +30.9% | news | Yahoo Finance | A Look At Iovance Biotherapeutics (IOVA) Valuation After Encouraging Amtagvi Data And Lung Cancer Fast Track Status - Yahoo Finance |
| 2026-02-24 | +30.9% | earnings | Yahoo Finance | Why Iovance Biotherapeutics (IOVA) Is Up 12.5% After Amtagvi-Fueled Q4 Beat And Narrower Loss - Yahoo Finance |
| 2026-02-24 | +30.9% | earnings | Yahoo Finance | Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance |
| 2026-02-24 | +30.9% | earnings | Quiver Quantitative | IOVANCE BIOTHERAPEUTICS ($IOVA) Releases Q4 2025 Earnings - Quiver Quantitative |
| 2026-02-24 | +30.9% | earnings | Investing.com | Earnings call transcript: Iovance Biotherapeutics Q4 2025 sees revenue beat, stock surges - Investing.com |
| 2026-02-24 | +30.9% | earnings | Stock Titan | Inside Iovance: 30% Q4 sales jump and FDA Fast Track for lung cancer TIL - Stock Titan |
| 2026-02-24 | +30.9% | analyst | Seeking Alpha | Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade) - Seeking Alpha |
| 2026-02-24 | +30.9% | news | Stock Titan | One-time cell therapy shrinks tough sarcomas in early Iovance trial - Stock Titan |
| 2026-02-24 | +30.9% | earnings | ChartMill | Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress - ChartMill |
| 2023-09-15 | +29.3% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-11-06 | +28.0% | news | Seeking Alpha | Iovance targets $1B-plus U.S. peak sales for Amtagvi as manufacturing shifts to internal facility |
| 2025-11-06 | +28.0% | earnings | Seeking Alpha | Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript |
| 2025-11-06 | +28.0% | earnings | Seeking Alpha | Iovance rises 34% as Q3 bottom line beat supported by strong Amtagvi sales |
| 2025-11-06 | +28.0% | earnings | Seeking Alpha | Iovance Biotherapeutics reports mixed Q3 results; reaffirms FY25 outlook |
| 2025-11-06 | +28.0% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2025-11-06 | +28.0% | earnings | Yahoo Finance | Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance |
| 2025-11-06 | +28.0% | earnings | Quiver Quantitative | IOVANCE BIOTHERAPEUTICS Earnings Results: $IOVA Reports Quarterly Earnings - Quiver Quantitative |
| 2025-11-06 | +28.0% | earnings | Stock Titan | Iovance Biotherapeutics (NASDAQ: IOVA) posts 43% gross margin as Q3 revenue reaches $68M - Stock Titan |
| 2025-11-06 | +28.0% | news | GlobeNewswire | Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results - GlobeNewswire |
| 2025-11-05 | +27.7% | earnings | Seeking Alpha | Iovance Biotherapeutics Q3 2025 Earnings Preview |
| 2024-08-09 | +26.6% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-08-08 | -26.0% | earnings | Seeking Alpha | Iovance falls after missing Q2 expectation |
| 2025-08-08 | -26.0% | earnings | Seeking Alpha | Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption |
| 2025-08-08 | -26.0% | earnings | Seeking Alpha | Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript |
| 2026-03-05 | +22.3% | news | Yahoo Finance | Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - Yahoo Finance |
| 2026-03-05 | +22.3% | news | Investing.com | Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com |
| 2026-03-04 | +22.0% | news | Seeking Alpha | Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years |
| 2026-03-04 | +22.0% | news | Seeking Alpha | Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years - Seeking Alpha |
| 2023-01-23 | +21.6% | legal | SEC EDGAR | IOVA 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-02-27 | -20.7% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2026-03-11 | -20.1% | news | Seeking Alpha | Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript |
| 2025-08-07 | -18.9% | earnings | Seeking Alpha | Iovance Biotherapeutics GAAP EPS of -$0.33 misses by $0.04, revenue of $60M misses by $7.14M |
| 2025-08-07 | -18.9% | legal | SEC EDGAR | IOVA 8-K: 2.02, 5.02 (SEC Filing) |
| 2024-05-09 | -18.8% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2026-03-06 | +18.6% | analyst | Yahoo Finance | Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target - Yahoo Finance |
| 2026-03-06 | +18.6% | news | Yahoo Finance | UBS Raises PT on Iovance Biotherapeutics (IOVA) - Yahoo Finance |
| 2026-03-06 | +18.6% | analyst | Quiver Quantitative | Iovance Biotherapeutics jumps as analysts lift targets and short interest fuels momentum - Quiver Quantitative |
| 2026-03-06 | +18.6% | legal | DirectorsTalk Interviews | Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Unpacking a 96% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews |
| 2023-05-30 | +16.3% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2026-03-12 | -16.1% | news | StocksToTrade | Iovance Biotherapeutics’ Latest Moves Shape Market Outlook - StocksToTrade |
| 2024-01-08 | +15.7% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2026-04-10 | -14.6% | news | Motley Fool | Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? |
| 2026-04-10 | -14.6% | analyst | Investing.com | Jefferies reiterates Iovance Biotherapeutics stock rating at buy - Investing.com |
| 2026-04-10 | -14.6% | expansion | NAI500 | A Melanoma Drug Successfully Launched, Yet Iovance’s Stock Has Underperformed the Market for Three Years - NAI500 |
| 2026-04-10 | -14.6% | news | simplywall.st | Iovance Biotherapeutics (IOVA) Is Up 16.9% After Stronger Real-World Amtagvi Data Spurs Franchise Hopes - simplywall.st |
| 2026-04-10 | -14.6% | news | Stocktwits | IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits |
| 2026-04-10 | -14.6% | news | The Motley Fool | Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? - The Motley Fool |
| 2026-04-10 | -14.6% | legal | MSN | REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN |
| 2024-11-07 | -14.0% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2024-11-08 | -13.8% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2023-03-27 | +12.3% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2026-01-16 | +12.0% | news | Yahoo Finance | Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed - Yahoo Finance |
| 2026-01-16 | +12.0% | news | Stock Titan | Biotech Iovance offers 97,710 stock options to 17 new hires at $2.22 - Stock Titan |
| 2023-07-11 | -11.9% | legal | SEC EDGAR | IOVA 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-12-19 | +11.8% | news | Yahoo Finance | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance |
| 2025-12-19 | +11.8% | news | Stock Titan | Cancer biotech offers stock options to new hires at $2.46 a share - Stock Titan |
| 2025-07-30 | -11.5% | news | Yahoo Finance | Is Iovance Biotherapeutics Stock Due for a Big Rally? - Yahoo Finance |
| 2022-01-10 | -11.4% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-07-15 | +11.0% | legal | SEC EDGAR | IOVA 8-K: 5.02, 8.01 (SEC Filing) |
| 2025-07-25 | -10.7% | news | Seeking Alpha | Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience |
| 2025-08-01 | +10.3% | news | Yahoo Finance | Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance |
| 2022-05-13 | +10.1% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-06-13 | -9.8% | legal | SEC EDGAR | IOVA 8-K: 5.02 (SEC Filing) |
| 2025-08-27 | -9.6% | news | Seeking Alpha | Iovance: Thin Margins, Dilution Threat Keep Risk Skewed |
| 2021-05-20 | +9.5% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-08-13 | +9.5% | earnings | Yahoo Finance | Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million - Yahoo Finance |
| 2024-02-28 | -9.2% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2024-06-03 | -9.0% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2023-08-08 | +8.9% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2026-01-09 | -8.9% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2026-01-09 | -8.9% | news | DirectorsTalk Interviews | Iovance Biotherapeutics (IOVA) Stock Analysis: A Potential 219% Upside in the Biotech Arena - DirectorsTalk Interviews |
| 2022-11-18 | -8.7% | legal | SEC EDGAR | IOVA 8-K: 1.01, 1.02 (SEC Filing) |
| 2022-11-18 | -8.7% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2023-07-10 | +8.6% | legal | SEC EDGAR | IOVA 8-K: 2.02, 8.01 (SEC Filing) |
| 2023-07-10 | +8.6% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-12-31 | -8.5% | legal | Yahoo Finance | Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review - Yahoo Finance |
| 2025-11-24 | +8.3% | news | Seeking Alpha | Iovance Biotherapeutics: Several Positives, But Competition Still Threatens |
| 2025-11-24 | +8.3% | news | Seeking Alpha | Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA) - Seeking Alpha |
| 2022-05-05 | -8.2% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2026-03-27 | -8.0% | news | Stock Titan | Vanguard (IOVA) shows 0 shares after Jan 12, 2026 realignment - Stock Titan |
| 2024-01-26 | +8.0% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2023-05-09 | +7.9% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2025-02-10 | -7.8% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2026-02-06 | +7.8% | earnings | Yahoo Finance | Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure - Yahoo Finance |
| 2026-04-11 | -7.5% | news | IndexBox | Iovance Biotherapeutics: Analyzing Growth Potential and Risks After Amtagvi Approval - IndexBox |
| 2026-04-21 | -7.0% | analyst | The Globe and Mail | Analysts Are Bullish on Top Healthcare Stocks: Definium Therapeutics (DFTX), Iovance Biotherapeutics (IOVA) - The Globe and Mail |
| 2025-11-11 | +6.9% | earnings | Seeking Alpha | Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode |
| 2025-11-11 | +6.9% | news | The Motley Fool | Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? - The Motley Fool |
| 2025-10-06 | -6.8% | news | Yahoo Finance | Iovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum Stalls - Yahoo Finance |
| 2026-04-22 | -6.6% | news | Insider Monkey | Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug |
| 2026-04-22 | -6.6% | earnings | MarketBeat | Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.4% - Here's What Happened - MarketBeat |
| 2026-04-22 | -6.6% | news | Yahoo Finance | Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug - Yahoo Finance |
| 2026-04-22 | -6.6% | earnings | MarketBeat | Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat |
| 2026-04-22 | -6.6% | legal | simplywall.st | Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative? - simplywall.st |
| 2022-02-24 | +6.5% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2025-08-09 | -6.4% | earnings | Yahoo Finance | Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance |
| 2024-05-24 | -6.2% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2026-04-09 | +6.1% | earnings | MarketBeat | Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 7.1% - Time to Buy? - MarketBeat |
| 2026-04-09 | +6.1% | news | Sahm | A Look At Iovance Biotherapeutics (IOVA) Valuation After Strong Amtagvi Data And Growing Pipeline Momentum - Sahm |
| 2026-03-20 | -5.5% | legal | SEC EDGAR | IOVA 8-K: 5.02 (SEC Filing) |
| 2026-03-20 | -5.5% | analyst | Yahoo Finance | Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi - Yahoo Finance |
| 2026-03-20 | -5.5% | executive | TipRanks | Iovance Biotherapeutics Announces Upcoming Board Member Retirement - TipRanks |
| 2026-03-20 | -5.5% | executive | Stock Titan | Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting - Stock Titan |
| 2025-09-28 | +5.4% | news | Seeking Alpha | Goldman's 48 potential M&A candidates |
| 2025-08-21 | +5.2% | news | Seeking Alpha | Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 |
| 2026-02-19 | +5.1% | news | Yahoo Finance | Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds? - Yahoo Finance |
| 2026-02-19 | +5.1% | news | Finviz | Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds? - Finviz |
| 2024-02-29 | -5.0% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-09-07 | -4.7% | earnings | Yahoo Finance | H.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization News - Yahoo Finance |
| 2025-09-19 | -4.3% | news | Yahoo Finance | Iovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost Cuts - Yahoo Finance |
| 2024-11-21 | +4.2% | legal | SEC EDGAR | IOVA 8-K: 1.01 and 1.02 (SEC Filing) |
| 2024-03-29 | -4.1% | legal | SEC EDGAR | IOVA 8-K: 5.02, 5.03 (SEC Filing) |
| 2021-05-06 | -3.9% | legal | SEC EDGAR | IOVA 8-K: 1.01, 2.02 (SEC Filing) |
| 2023-11-07 | -3.8% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2026-04-13 | -3.8% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Is Iovance Biotherapeutics (IOVA) Stock Good for Portfolio | Price at $3.49, Down 5.68% - Trend Analysis - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-06 | -3.7% | M&A | MarketBeat | Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster |
| 2023-12-27 | -3.7% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2023-01-11 | +3.6% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2021-06-29 | -3.5% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2026-04-15 | +3.4% | M&A | BioPharma Dive | Obsidian, Galera to advance cell therapy following reverse merger |
| 2026-04-20 | -3.3% | news | Insider Monkey | Chardan Maintains a Buy on Iovance Biotherapeutics (IOVA) |
| 2026-04-20 | -3.3% | news | Yahoo Finance | Chardan Maintains a Buy on Iovance Biotherapeutics (IOVA) - Yahoo Finance |
| 2022-08-29 | -3.2% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-10-23 | +3.2% | news | Yahoo Finance | Iovance Biotherapeutics (IOVA): Exploring Valuation After a Prolonged Share Price Decline - Yahoo Finance |
| 2025-10-23 | +3.2% | news | Yahoo Finance | Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 - Yahoo Finance |
| 2026-03-25 | +3.2% | news | simplywall.st | Is Iovance Biotherapeutics (IOVA) Offering A Compelling Opportunity After Recent Price Swings? - simplywall.st |
| 2026-03-16 | -3.1% | earnings | MarketBeat | Invenomic Capital Management LP Buys 2,246,945 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat |
| 2023-06-16 | -2.9% | legal | SEC EDGAR | IOVA 8-K: 1.01, 1.02 (SEC Filing) |
| 2026-03-26 | -2.9% | earnings | Zacks | Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound? |
| 2026-03-26 | -2.9% | news | Simply Wall St. | Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge |
| 2026-03-26 | -2.9% | news | Yahoo Finance | Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - Yahoo Finance |
| 2026-04-23 | -2.9% | legal | Sahm | Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative? - Sahm |
| 2025-07-03 | -2.9% | legal | SEC EDGAR | IOVA 8-K: 5.02 (SEC Filing) |
| 2022-06-13 | -2.8% | legal | SEC EDGAR | IOVA 8-K: 5.02, 5.07, 8.01 (SEC Filing) |
| 2023-05-18 | -2.7% | legal | SEC EDGAR | IOVA 8-K: 2.01 and (SEC Filing) |
| 2025-12-08 | +2.7% | news | Yahoo Finance | Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Yahoo Finance |
| 2025-12-08 | +2.7% | news | Yahoo Finance | Weighing Iovance Biotherapeutics After a 71.8% Slide and DCF Upside in 2025 - Yahoo Finance |
| 2023-02-28 | +2.6% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2026-04-07 | +2.6% | news | Seeking Alpha | Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback |
| 2025-08-18 | +2.5% | news | Seeking Alpha | Iovance gets conditional Health Canada approval for Amtagvi |
| 2021-08-05 | +2.4% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2025-12-29 | -2.3% | news | Seeking Alpha | Iovance Biotherapeutics: Bright Prospects For 2026 |
| 2025-12-29 | -2.3% | news | Seeking Alpha | Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA) - Seeking Alpha |
| 2026-02-07 | +2.3% | news | Yahoo Finance | Is It Time To Reconsider Iovance Biotherapeutics (IOVA) After Prolonged Share Price Weakness - Yahoo Finance |
| 2026-02-07 | +2.3% | news | Yahoo Finance | Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility - Yahoo Finance |
| 2026-01-10 | -2.2% | earnings | The Globe and Mail | Iovance Highlights Amtagvi Momentum and Confirms 2025 Guidance - The Globe and Mail |
| 2024-02-22 | -2.1% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2023-07-13 | -2.1% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2023-04-24 | -2.0% | legal | SEC EDGAR | IOVA 8-K: 5.02 and (SEC Filing) |
| 2025-08-19 | +2.0% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-08-19 | +2.0% | news | Yahoo Finance | Why Iovance Biotherapeutics Stock Was Climbing Today - Yahoo Finance |
| 2025-10-17 | +2.0% | news | Yahoo Finance | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance |
| 2026-02-26 | +1.8% | earnings | Yahoo Finance | Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success - Yahoo Finance |
| 2026-02-26 | +1.8% | news | Stock Titan | Cancer biotech Iovance plans March talks at TD Cowen and Barclays events - Stock Titan |
| 2026-02-20 | +1.7% | news | Stock Titan | Iovance gives new hires stock options at $2.85 per share - Stock Titan |
| 2026-04-17 | -1.5% | news | GlobeNewswire | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
| 2026-04-17 | -1.5% | news | Simply Wall St. | Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? |
| 2026-04-17 | -1.5% | news | Yahoo Finance | Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? - Yahoo Finance |
| 2026-04-17 | -1.5% | news | Stock Titan | Iovance offers 135,470 stock options to 12 new hires - Stock Titan |
| 2026-04-17 | -1.5% | news | simplywall.st | Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Three Month Share Price Surge - simplywall.st |
| 2026-04-17 | -1.5% | news | GlobeNewswire | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire |
| 2026-04-17 | -1.5% | news | Stock Titan | Iovance Biotherapeutics (NASDAQ: IOVA) seeks votes on ESPP + share increase - Stock Titan |
| 2026-04-17 | -1.5% | news | The Manila Times | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times |
| 2026-02-11 | -1.5% | news | Yahoo Finance | Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 - Yahoo Finance |
| 2026-02-11 | -1.5% | news | Stock Titan | Cancer biotech Iovance sets Feb. 24 call on 2025 results, plans - Stock Titan |
| 2026-02-11 | -1.5% | earnings | Quiver Quantitative | Iovance Biotherapeutics to Host Conference Call for Q4 and Full Year 2025 Financial Results on February 24, 2026 - Quiver Quantitative |
| 2025-11-08 | +1.5% | analyst | simplywall.st | Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results - simplywall.st |
| 2025-08-22 | -1.5% | legal | SEC EDGAR | IOVA 8-K: 1.01 and (SEC Filing) |
| 2025-08-22 | -1.5% | news | Quiver Quantitative | Iovance Biotherapeutics Grants Inducement Stock Options to New Employees - Quiver Quantitative |
| 2022-09-12 | +1.4% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2022-08-04 | +1.4% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2021-09-23 | -1.4% | legal | SEC EDGAR | IOVA 8-K: 5.02 and (SEC Filing) |
| 2025-10-10 | -1.1% | earnings | Seeking Alpha | Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play |
| 2026-01-15 | -1.0% | news | Yahoo Finance | Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory - Yahoo Finance |
| 2026-01-15 | -1.0% | news | Yahoo Finance | Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns - Yahoo Finance |
| 2021-06-14 | +0.9% | legal | SEC EDGAR | IOVA 8-K: 5.02 and 5.07 (SEC Filing) |
| 2025-11-07 | +0.9% | news | Yahoo Finance | Is Iovance Biotherapeutics (IOVA) Undervalued? A Fresh Look at Valuation After Recent Share Price Rebound - Yahoo Finance |
| 2024-06-28 | +0.8% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2022-01-19 | -0.8% | legal | SEC EDGAR | IOVA 8-K: 5.02 and (SEC Filing) |
| 2024-03-04 | -0.7% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-08-29 | -0.5% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2025-08-29 | -0.5% | news | Yahoo Finance | Iovance Biotherapeutics (IOVA) Raises US$350 Million in Equity Offering - Yahoo Finance |
| 2025-10-13 | -0.5% | news | Yahoo Finance | Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? - Yahoo Finance |
| 2025-10-13 | -0.5% | news | The Motley Fool | Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? - The Motley Fool |
| 2026-02-27 | +0.4% | news | Yahoo Finance | Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately - Yahoo Finance |
| 2022-11-03 | -0.4% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2023-08-18 | -0.4% | legal | SEC EDGAR | IOVA 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-02-10 | +0.3% | news | Seeking Alpha | Top Quant rated bullish small cap stocks among companies with high short interest |
| 2021-11-04 | -0.3% | legal | SEC EDGAR | IOVA 8-K: 2.02 and (SEC Filing) |
| 2026-03-31 | +0.2% | news | Seeking Alpha | Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help |
| 2026-03-31 | +0.2% | news | Seeking Alpha | Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help (NASDAQ:IOVA) - Seeking Alpha |
| 2022-04-05 | -0.2% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2024-04-03 | -0.1% | legal | SEC EDGAR | IOVA 8-K: 8.01 and (SEC Filing) |
| 2026-02-25 | -0.0% | earnings | Investing.com | Iovance Biotherapeutics stock rating upgraded on revenue growth - Investing.com |
| 2026-02-25 | -0.0% | news | 24/7 Wall St. | Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why - 24/7 Wall St. |
| 2026-02-25 | -0.0% | analyst | Stocktwits | After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits |
| 2026-04-26 | — | news | Insider Monkey | Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now? |
| 2026-04-26 | — | news | simplywall.st | Is Iovance Biotherapeutics (IOVA) Offering Value After Recent Share Price Volatility? - simplywall.st |